Сравнительная оценка влияния нифедипина продленного действия и метопролола на тромбоцитарно-сосудистое звено гемостаза у больных эссенциальной артериальной гипертензией
Диссертация
Сосудистый эндотелий, с одной стороны, является мишенью для неблагоприятного воздействия факторов риска атеросклероза (АГ, дислипидемия, курение и др.) на сосудистую стенку, а с другой — ключевым фактором атерогенеза и атеротромбоза. В связи с этим эндотелиальная дисфункция (ЭД) рассматривается многими авторами как оптимальная промежуточная конечная точка для определения риска СС осложнений… Читать ещё >
Список литературы
- Александров A.A. Распределение жира в организме: с чем связаны его прогностические свойства в отношении сердечнососудистой заболеваемости /A.A. Александров //Кардиология.-1996.-№ 3.-С.57−62.
- Алмазов В.А. Длительная терапия больных мягкой артериальной гипертонией (результаты пятилетнего наблюдения) / В. А. Алмазов, И. С. Бродская, Е. В. Шляхто // Тер. архив.-1992.-№ 9.-С. 94−97.
- Алмазов В.А. Синдром инсулинорезистентности / В. А. Алмазов, Я. В. Бродская, Е. В. Шляхто // Артериальная гипертен-зия.-1997.-Т.З.-№ 1.-С.7−17.
- Алмазов В.А. Метаболический сердечно-сосудистый синдром / В. А. Алмазов, Я. В. Благосклонная, Е. В. Шляхто.-СПб.: Изд-во СПбГМУ.-1999.-208 с.
- Аметов A.C. Ожирение эпидемия XXI века /A.C. Аметов // Тер. Архив.-2002.-Т.74.-№ 10.-С. 5−7.
- Арабидзе Г. Г. Диагностика и лечение артериальной гипертонии (Методические рекомендации / Г. Г. Арабидзе, Ю. Б. Белоусов, Ю. В. Варакин.-М.:Рус.вр.-1997.-95 с.
- Беленков Ю.Н. Первое российское национальное многоцентровое исследование РОСА (Российское исследование Оптимального Снижения Артериального давления) / Ю. Н. Беленков, И. Е. Чазова // Артериальная гипертензия.-2003.-№ 5.-С.7−9.
- Белоусов Ю.Б. Антагонисты кальция пролонгированного действия /Ю.Б.Белоусов // Кардиология.-2001 .-№ 4.-С.89−93.
- Бова A.A. Роль дисфункции эндотелия в патогенезе артериальной гипертонии / A.A. Бова // Мед. новости.-2001 .-№ 1.-С. 25−29.
- Бойцов С.А. Что мы знаем о патогенезе артериальной ги-пертензии / С. А. Бойцов //Consilium-medicum.-2004.-№ 5.-T. 6.-С.45−48.
- Вопросы медицинской статистики/Под редакцией С. Г. Резникова, В. Г. Лопушанского.-Омск: ОмскКнига.-1988.-132 с.
- Габбасов З.А. Новый высокочувствительный метод анализа агрегации тромбоцитов / З. А. Габбасов, Е. Г. Попов, Ю.А. Гав-рилов и др. // Лаб. дело.-1989.-№ 10.-С. 15−18.
- Диденко В.А. Метаболический синдром X: история вопроса и этиопатогенез /В.А. Диденко // Лаб. мед.-1999.-№ 2.-С. 4957.
- Зимин Ю.В. Происхождение, диагностическая концепция и клиническое значение синдрома инсулинорезистентности или метаболического синдрома X / Ю. В. Зимин // Кардиология.-1998.-№ 6.-С. 71−81.
- Карпов Ю.А. Лечение стабильной стенокардии: учет метаболических нарушений / Ю. А. Карпов // Русский медицинский журнал.- 2001.-№ 9.-С.62−64.
- Карпов Ю.А. Клиническая гипертензиология: анализ завершенных исследований / Ю. А. Карпов // Кардиология.-2002.-№ 10.-С.63−66.
- Лупанов В.П. Ожирение как фактор риска развития сердечно-сосудистых катастроф / В. П. Лупанов // Русский медицинский журнал.-2003.-№ 6.-С. 125 127.
- Маколкин В.И. Гипертоническая болезнь/В.И.Маколкин, В. И. Подзолков.-М.:Рус.врач.-2000.-96 с.
- Мамедов М.Н. Связь абдоминального типа ожирения и синдрома инсулинорезистентности у больных артериальной гипертонией /М.Н. Мамедов, Н. В. Перова, В. А. Метельская // Кардиология.-1999.-№ 9.-С. 18−22.
- Мамедов М.Н. Руководство по диагностике и лечению метаболического синдрома / М. Н. Мамедов.-М.: Полиграф Хол-динг-Мульти-принт, 2004.-24 С.
- Манухина Е.Б. Эндотелиальная дисфункция и артериальная гипертензия: механизмы и пути коррекции / Е. Б. Манухина //Кардиоваск. терапия и профилактика.-2003.-Т.2.-№ 4.-С.26−30.
- Мингазетдинова JI.H. Артериальная гипертония с метаболическим синдромом: влияние на тромбоцитарно-сосудистое звено гемостаза / J1.H. Мингазетдинова, Э. Г. Муталова, Н. П. Каневская // Артериальная гипертензия.-2004.-№ 4.-С.21−25.
- Моисеев B.C. Гипертония, сахарный диабет, атеросклероз -клинические проявления метаболического синдрома X. Перспективы фармакологической коррекции / B.C. Моисеев, А. Я. Ивлева, Ж. Д. Кабалава // Вестник РАМН.-1995.-№ 5.-С. 15 -18.
- Мухин H.A., Новая форма нифедипина (Нифекард XL) в лечении артеральной гипертонии / H.A. Мухин, И. Г. Фомина, В. А. Люсов // Клиническая фармакология и терапия.-2003.-№ 3-С. 1−4.
- Нагорнев В.А. Атерогенез и иммунное воспаление/ В.А. На-горнев, В. Х. Анестиади, Е. Г. Зота.- М., 1997.-325 с.
- Оганов Р. Г. Гиперинсулинемия и артериальная гипертония: возвращаясь к выводам United Kingdom Prospective Diabetes Study / P.Г. Оганов, A.A. Александров // Русский медицинский журнал.-2002.-№ 10.-С. 486 491.
- Оганов Р.Г. Факторы риска и профилактика сердечнососудистых заболеваний / Р. Г. Оганов // Качество жизни. Медицина.-2003.-№ 2.-С. 10−13.
- Оганов Р.Г. Сочетание компонентов метаболического синдрома у лиц с артериальной гипертонией и их связь с дисли-пидемией /Р.Г. Оганов// Тер. архив.-1998.-№ 12.-С. 19−23.
- Оганов Р.Г. Профилактика сердечно-сосудистых заболеваний: возможности практического здравоохранения /Р.Г. Оганов // Кардиоваск. тер. и проф.-2002.-№ 1.-С. 5−9.
- Перова Н.В. Методы раннего выявления и коррекции метаболического синдрома /Н.В. Перова, В. А. Метельская, М. Н. Мамедов // Профилактика заболеваний и укрепления здоровья.-2001.-№ 4.-С.18−31.
- Перова Н.В. Суммарный риск ИБС и показания к лечению гиперхолестеринемии (применение европейских рекомендаций 1994 г. к российским условиям) / Н. В. Перова // Кардиология.-1996.-№ 3.-С. 47−53.
- Перова Н.В. Кластер факторов риска сердечно-сосудистых заболеваний: метаболический синдром / Н. В. Перова, М. Н. Мамедов, В. А. Метельская // Междунар. мед. журнал.-1999.-№ 2.-С.21−24.
- Перова Н.В. Патогенетические основы метаболического синдрома как состояния высокого риска атеросклеротических заболеваний /Н.В. Перова, В. А. Метельская, Р. Г. Оганов //Международный медицинский журнал.-2001 .-№ 7.-С. 6−10.
- Преображенский Д.В. Амлодипин антагонист кальция III поколения /Д.В.Преображенский, Б. А. Сидоренко, E.H. Шибаев // Кардиология.-1998.-№ 2.-С.66−73.
- Смиешко В.Н. Чувствительность малой артерии мышечного типа к скорости кровотока: реакция самоприспособления просвета артерии / В. Н. Смиешко, В. М. Хаютин, М. А. Герова и др. // Физиол. журн. СССР.- 1979.-№ 2.-С. 291−298.
- Фирсов H.H. Реологические свойства крови и патология сердечно-сосудистой системы / H.H. Фирсов // Тромбоз, гемостаз, реология.-2002.-№ 2.-С.26−31.
- Шестакова М.В. Дисфункция эндотелия причина или следствие метаболического синдрома? / М. В. Шестакова // Русский медицинский журнал.-2001 .-№ 9.-С.88−90.
- Шестакова М. В. Сердечно сосудистые факторы риска у пожилых больных сахарным диабетом 2 типа и методы их коррекции / М. В. Шестакова, JI.A. Чугунова, М. Ш. Шамхалова // Русский медицинский журнал.-2002.-№ 10.-С. 480 — 485.
- Шилов A.B. Артериальная гипертензия и метаболический синдром X / A.B. Шилов, М. В. Чубаров, М. В. Мельник // Русский медицинский журнал.-2003.-№ 21.-С. 12 17.
- Шостак H.A., Аничков Д. А. К вопросу о диагностических критериях метаболического синдрома / H.A. Шостак, Д. А. Аничков // Русский медицинский журнал.-2002.-№ 27.-С. 1255 1257.
- Чазова И.Е. Роль антагонистов кальция в лечении артериальной гипертензии /И.Е.Чазова //Тер. Архив.-2001 .-№ 8.-С.80−83.1.l
- Чазова И. Е. Метаболический синдром и артериальная гипертония / И. Е. Чазова, В. Б. Мычка // Consilium-medicum.-2002.-№ 11.-С. 587 590.
- Федеральное руководство для врачей по использованию лекарственных средств (формулярная система). Выпуск III /под редакцией Чучалина А. Г., Волкова А. И., Белоусова Ю.Б.-М.:Эхо.-2002.-С. 80−83.
- Юнкеров В.И. Математико-статистическая обработка данных медицинских исследований / В. И. Юнкеров, С. Г. Григорьев.-СПб.: ВМедА, 2002.-266 с.
- Anderson K.M. An updated coronary risk profile. A statement for health professionals / K.M. Anderson, P.W. Wilson, P.M. Odell et al. // Circulation.-1991 .-Vol.83.-P.356−362.
- Anderson T.J. Close relation of endothelial function in the human coronary and peripheral circulations / T.J. Anderson, A. Uehata, M. Gerhard et al.// J. Am. Coll. Cardiol.-1995.-Vol.26.-P.1235−1241.
- Anfossi G. Role of catecholamines in platelet function: pathophysiological and clinical significance / G. Anfossi, M. Trovati // Eur. J. Clin. Invest. 1996.-Vol.26.-P.353−370.
- Angus J.A. New insights into vascular reactivity: from altered structure to neural control / J.A. Angus // Clin. Exp. Pharmacol. Physiol.-1998.-Vol.24.-№ 5.-P.297−304.
- Armas-Padilla M.C. Effect of lacidipine and nifedipine GITS on platelet function in patients with essential hypertension / M.C. Armas-Padilla, M.J. Armas-Hernandez, M. Hernandez-Hernandez et al. // J. Hum. Hypertens.-2000.-Vol. 14.-Suppl. 1 .-P.91−95
- Armas-Hernandez M.J. Platelet aggregation and malondialde-hide production in hypertensive and healthy volunteer / M.J. Armas-Hernandez//Am. J. Hypertens.- 1994.-Vol.2.-P.91−95.
- Avanzini F. INSIGHT and NORDIL / F. Avanzini, G. Tognoni // Lancet.-2000.-Vol.356.-P. 1927−1928.
- Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials // Lancet.-2000.-Vol.356.-P. 19 551 964.
- Boneu B. Factor VIII complex and endothelial damage / B. Boneu, M. Abbal, J. Plante et al. // Lancet.-1975.-Vol.1.-P.1430−1435.
- Blann A.D. Hypothesis: Is soluble P-selectin a new marker of platelet activation in essential hypertension? / A.D. Blann, G.Y.H. Lip. // J. Cardiovasc.-1984.-Vol.6.-P. 840−843.
- Blann A.D. Von Willebrand factor and endothelial damage in essential hypertension / A.D. Blann, T. Naqvi, M. Waite et al. // J. Hum. Hypertens.-1993.-Vol. 7.-P.107−111.
- Blann A.D. Von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis / A.D. Blann, M.A. Waite // Coron. Artery. Dis.-1996.-Vol.7.-P. 143−147.
- Blann A.D. Evidence of platelet activation in hypertension / A.D. Blann, G.Y.N. Lip, I.F. Islim et al. // J. Hum. Hypertens.-1997-Vol. 11.-P. 607−609.
- Blann A.D. Soluble P-selectine in atherosclerosis- a comparison with endothelium cells and platelet markers / A.D. Blann, G.Y.N. Lip, D.G. Beevers et al. // Thromb. Haemost.-1997.-Vol.77.-№ 6.-P. 1077−1080.
- Blann A.D. Pharmacological modulation of platelet function in hypertension. Brief review/ A.D. Blann, S. Nadar, G.Y.N. Lip et al. // Hypertension.-2003.-Vol.42.-P.1−12.
- Boffa M.C. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker / M.C. Boffa // Haemostasis.-1996.-Vol. 26.-P.233−243.
- Bowman A.J. Nitric oxide mediated venodilator effect of nebivolol / A.J. Bowman, C.P. Chen, G.A. Ford et al. // Br. J. Clin. Pharmacol.-1994.-Vol.38.-P. 199−204.
- Brovkovych V. Synergistic antihypertensive effects of nifedipine on endothelium. Concurrent release of NO and scavenging of superoxide / V. Brovkovych, L. Kalinowski, R. Muller-Peddinghaus et al. // Hypertension.-2001 .-Vol.37.-№.34.-P. 134 136.
- Brush J.E. Abnormal endothelium-dependent coronary vasomo-tion in hypertensive patients / J.E. Brush, D.P. Faxon, S. Salmon // J. Am. Coll. Cardiol.-1992-Vol.19.-P.809−815.
- Bruning T.A. In vivo characterization of muscarinic receptor subtypes that mediate vasodilation in patients with essential hypertension / T.A. Bruning, P.C. Chang, G.C. Hendriks // Hypertension.-1995.-Vol.2 6.-P.7 0−77.
- Burnett J.C. Jr. Coronary endothelial function in health and disease / J.C. Jr. Burnett // Drugs.-1997.-Vol. 53.-№.1.-P. 20−29.
- Catapano A.L. Calcium antagonists and atherosclerosis / A.L. Catapano // Exper. Evid. Eur. Heart J.-1997.-vol.l8.-Suppl A.-P.A80-A86.
- Cappelli-Bigazzi M. Effects of high-cholesterol and atherogenic diets on vascular relaxation in spontaneously hypertensive rats / M. Cappelli-Bigazzi, S. Rubattu, C. Battaglia et al. // Am. J. Physiol.-1997.-Vol. 273.-P.647−654.
- Carlberg B. Atenonolol and cardiovascular morbidity. Results of meta-analysis / B. Carlberg // Lancet.-2004.-Vol.364.-P. 16 841 689.
- Carretero O.A. Essential hypertension. Part I: definition and etiology / O.A. Carretero, S. Oparil // Circulation.-2000.-Vol.101.-P. 329−335.
- Celermayer D.S. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis / D.S. Celermayer, K.E. Sorensen, V.M. Gooch et al. // Lancet.-1992.-Vol.340.-P. 1111−1115.
- Cockroft J.R. Preserved endothelium-dependent vasodilation in patients with essential hypertension / J.R. Cockroft, P.J. Chowienczyck, N. Benjamin // N. Engl. J. Med.-1994.-Vol.300.-P.1036−1040.
- Cockcroft J.R. Hyperlipidaemia, hypertension, and coronary heart disease / J.R. Cockcroft, P.J. Chowienczyk, J.M. Ritter // Lancet.-1995.-Vol. 345.-P.862−863.
- Cockcroft J.R. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism / J.R. Cockcroft, P.J. Chowienczyk, S.E. Brett // J. Pharmacol. Exp. Ther.-1995.-Vol.274.-P. 1067−1071.
- Contreras F. Endothelial dysfunction in arterial hypertension / F. Contreras, M. Rivera, J. Vasquez et al. // J. Hum. Hypertens.-2000.-Vol.14.- Suppl 1.-S20-S25.
- Conroy R.M. On behalf of the SCORE project group. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the
- SCORE project / R.M. Conroy, K. Pyorala, A.P. Fitzgerald et al. // Eur. Heart J.-2003.-Vol. 114.-P. 123−128.
- Chobanian A. V. Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease / A. V. Chobanian // Cur. Hypertens. Rep.-2002.-Vol. 4.-P.93−95.
- Chowienczyk P.J. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia / P.J. Chowienczyk, G.F. Watts, J.R. Cockroft // Lancet.-1992.-Vol.340.-P. 1430−1432.
- Creager M.A. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans / M.A. Creager, Cooke J.P., M.E. Medelsohn // J. Clin.Invest. 1990.-Vol.86.-P. 228−234.
- Creager M.A. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans / M.A. Creager., S.J. Gallagher, J.G. Xavier // J. Clin. Invest.-1992.-Vol.90.-P. 12 481 253.
- Cruickshank J. The current role of beta-blockers in cardiovascular medicine / J. Cruickshank // Rev. Contemp. Pharmacother.-1997.-Vol.8.-P.1−19.
- Culer J.A. High blood pressure and end-organ damage / J.A. Culer // J.Hypertens.-1996.-Vol.14.-Suppl.6.-S3-S6.
- Dahlof B. Cardiovascular morbidity and mortality in the Losarian Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol / B. Dahlof, R.B.
- Devereux, S.E. Kjeldsen et al. // Lancet.- 2002.-Vol.359.-P.995−1003.
- Ding Y. Nifedipine and Niltiazem but not verapamil up-regulate endothelial nitric oxide synthase expression/ Y. Ding, N.D. Vaziri // J.Pharmacol. Exp. Ther.-2000.-Vol.292.-P.606−609.
- Dhein S. Actions of 1,4-dihydropridines in isolated mesenteric vascular beds / S. Dhein, Y. Zhao, S. Simsek et al. // J. Cardio-vasc. Pharmacol.-1995.-№ 26.-P.784−791.
- Dhein S. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide / S. Dhein, A. Salameh, R. Berkels et al. // Drugs.-1999.-Vol. 58.-P.397−404.
- Dohi Y. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: stadues in perfused mesenteric resistance arteries / Y. Dohi, L. Criscione, K. Pfeiffer et al. // J.Cardiovasc.Pharmacol.-1994.-Vol.24.-P. 372−379.
- Doi H. Membrane active lipids in remnant lipoproteins cause impairment of endothelium-dependent vasorelaxation / H. Doi, K. Kugiyama, M. Ohgushi et al. // Arterioscler. Thromb. Vase. Biol.-1999.-Vol.19.-P.1918−1924.
- Drexler H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine / H. Drexler, A.M. Zeiher, K. Meinzer // Lancet.-1991.-Vol.338.-P.1546−1550.
- Dzau V.J. Endothelium and growth factors in vascular remodeling of hypertension / V.J. Dzau, G.N. Gibbon // Hypertension.-1991.-Vol. 18.-Suppl. III.-P.l 15−121.
- Eliasson M. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden
- MONICA Study / M. Eliasson, P.E. Evrin, D. Lundblad // J. Clin. Epidemiol.-1994.-Vol.47.-P.5 13−524.
- Falciani M. Effects of nebivolol on human platelet aggregation / M. Fal ciani, B. Rinaldi, B. D’Agostino et al. // J. Cardiovasc. Pharmacol.-2001.-Vol.3 8.-P.922−929.
- Feuerstein G.Z. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection / G.Z. Feuerstein, R.R. Ruffolo // Eur. Heart. J.-l995.-Vol. 16.-Suppl. F.-P.38−42.
- Frielingsdorf J. Normalization of abnormal coronary vasomo-tion by calcium antagonists in patients with hypertension / J. Frielingsdorf, C. Seiler, P. Kauffman et al. // Circulation.-1996.-Vol.93.-P.1380−1387.
- Freedman J.E. Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols/ J.E. Freedman, B. Frei, G.N. Welch et al. // J.Clin.Invest.-1995.-Vol.96.-P.394−400.
- Frohlich E. D. Local hemodynamic changes in hypertension insights for therapeutic preservation of target organs/ E. D. Frohlich // Hypertension.-2001.-Vol.38.-P.1388−1393.
- Gao Y.S. Nebivolol induces endothelium-dependent relaxations of canine arteries/ Y.S. Gao, T. Nagao, R.A. Bond et al. // J.Cardiovasc. Pharmacol.-1991.-Vol. 17.-P.964−969.
- Gardiner S.M. Control of regional blood flow by endothe-lium-derived nitric oxide/ S.M. Gardiner, A.M. Compton, T. Bennet, R.M.J.Palmer // Hypertension.-1990.-Vol. 15.-P.486−492.
- Gl ueck C.J. Betablockers, Lp (a), hypertension, and reduced basal fibrinolytic activity / C.J. Glueck, H.I. Glueck, T. Hamer // Am. J. Med. Sei.-1994.-Vol.307.-P.3 1 7−324.
- Granstam S.O. Influences of Carvedilol treatment on the effects of acetylcholine on regional hemodynamics in the spontaneously hypertensive rats/ S.O. Granstam, B. Fellstom, L. Lind // Clin.Sci.-1998.-Vol 95.-P.303−309.
- Griendling K.K. Oxidative stress and cardiovascular disease / K.K. Griendling, R.W. Alexander // Circulation.-1997.-Vol.96.-P.3264−3265.
- Grimm R.H. Long-term effects on plasma lipids of diet and drugs to treat hypertension/ R.H. Grimm, J.M. Flack, G.A. Gran-dits et al. // J.A.M.A.-1996.-Vol.275.-P.1549−1556.
- Gokce N. Risk stratification for postoperative cardiovascular events via noninvasive assessment of end-thelial function / N. Gokce, J.F. Keaney Jr., J.O. Menzoian et al. // Circulation.-2002.-Vol.105.-P. 1567−1572.
- Gunther J. Nitric oxide enhances the vasorelaxing effect of nitrendipine in various isolated arteries/ J. Gunther, S. Dhein, R. Rosen et al. // Basic. Res. Cardiol.-1992.-Vol.87.-P.452−460.
- Haffner S. Insulin and blood pressure in the San Antonio heart study: a review/ S. Haffner // Cardiovasc. Risk Factors.-1993.-№ 1.-P.18−27.
- Haller H. Endothelial function. General consideration/ H. Haller // Drugs.-1997.-Vol.53.-Suppl.l-P.1−10.
- Halcox J.P.J. Prognostic value of coronary vascular endothelial function/ J.P.J. Halcox, W.H. Schenke, G. Zalos et al. // Hypertension.-2002.-Vol. 106.-P. 6 5 3−65 8.
- Hayakawa H. Mechanisms foraltered endothelium-dependent vasorelaxation in isolated kidneys from experimental hypertensive rats/ H. Hayakawa, Y. Hirata, E. Suzuki et al. // Am. J. Physiol.-1993.-Vol.264.-P. 1535−1541.
- Hayakawa H. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy/ H. Hayakawa, K. Coffee, L. Raij // Circulation.-1997.-Vol.96.-P. 2407−2413.
- Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction/ D.G. Harrison // J. Clin. Invest.-1997.-Vol.100.-P.2153−2157.
- Hasdai D. Coronary endothelial dysfunction is associated with myocardial perfusion defects/ D. Hasdai, R.J. Gibbons, D.R. Holmes Jr. // Circulation.-1997.-Vol.96.-P.3390−3395.
- Hedner T. Measures of endothelial function as an endpoint in hypertension? IT. Hedner, X.Y. Sun // Blood Pressure.-1997.-Vol. 6.-Suppl 2.-P.58−66.
- Hedner T. Endothelial Dysfunction—A Challenge for Hypertension Research/ T. Hedner, L. Hansson, A. Himmelmann // Blood Pressure.- 2000.- Vol. 9.- P.2−3
- Heitzer T. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL/ T. Heitzer, S. Yla-Herttuala, J. Luoma et al. // Circulation.-1996.-Vol.93.-P.1347−1353.
- Heitzer T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease/ T. Heitzer, T. Schlinzig, K. Krohn et al. // Circulation. 2001.-Vol.104.-P.2673−2678.
- Henry P.D. Calcium antagonist and atherosclerosis. Editorial./ P.D. Henry // Arteriosclerosis.-1990.-Vol.10.-P.963−965.
- Hernandez R. Amlodipine in hypertension: its effects on platelet aggregation and dynamic exercise /R. Hernandez // J. Cardiovasc. Pharmacol.-1991 .-Vol. 17.-P.25−27.
- Hernandez R. Effects of amlodipine on platelet aggregation and blood pressure in patients with essential hypertension / R. Hernandez, A.R. Carvajal, M.J. Hernandez et al. // Clin.Ther.-1993.-Vol.15.-P.304−313.
- Hernandez R. Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension / R. Hernandez // Int. J. Clin. Pharmacol. Ther. 1999.Vol.37.-P. 323 331.
- Hor R. Hemodynamic, antivasoconstructor, and antiathero-sclerotic effects of calcium antagonist in animal models of atherosclerosis/ R. Hor, C. Tapparelli, D. Weistein. // J.Cardiovasc. Pharmacol.-1990.-Vol. 15.-Suppl 1.-S7-S12.
- Houghton J.L. Heterogeneous vasomotor responses of coronary conduit and resistance vessels in hypertension/J.L. Houghton, C.A. Davidson., P.A. Kuhner // J. Am. Coll. Cardiol.-1998.-Vol.31.-P.374−382.
- Hypertension Detection and Follow-up Program. The effect of treatment on mortality in 'mild' hypertension- results of the Hypertension Detection and Follow-up Program.'// N. Engl. J. Med.-1982.-Vol.307.-P.976−980.
- Ignarro L. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide/ L. Ignarro, C. Napoli, J. Loscalzo et al. // Circulation Research.-2002.-Vol.90.-P.21−25.
- Iiyama K. Impaired endothelial function with essential hypertension assessed by ultrasonography/ K. Iiyama, M. Nagano, Y. Yoshikage et al. // Am. Heart. J.-1996.-Vol.132.-P.779−782.
- Ikeda Y. Inhibition of human platelet functions by verapamil/ Y. Ikeda // Thromb. Haemost.-1981.-Vol. 30.-P.158−161.
- Imazu M. Hypertension and insulin disorders/ M. Imazu // Cur. Hypertens. Rep.-2002.-Vol. 4.-P.477−482.
- IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the betablocker Oxprenolol: the International Prospective Primary Prevention Study in Hypertension // J. Hypertens.-1985.-Vol.3.-P. 379 392.
- Isomaa B. Cardiovascular morbidity and mortality consists with metabolic syndrome/ B. Isomaa, K. Lahti, P. Almgren et al. // Diab. Car.- 2001 .-Vol.24.-P.683−689.
- Isumi Y. Regulation of adrenomedullin production in rat endothelial cells/ Y. Isumi, H. S. Shoji, Sugo et al. // Endocrinology.- 1998.-Vol. 13 9.-P. 8 38−846.
- Jackson C.L. Mechanism of antiatherogenic action of calcium antagonists/C.L. Jackson, R.C. Bush, D.E. Bowyer// Atherosclerosis." 19 89.-Vol.8 0.-P. 17−26.
- Jahn B. Oxygen radical generation in human platelets: dependence on 12-lipoxygenase activity and on the glutathione cycle/ B. Jahn, G.M. Hansch // Int.Arch.Allergy. Immunol.-1990.-Vol.93.-P.73−79.
- James I.M. Treatment of hypertension with Captopril: preservation of regional blood flow and reduced platelet aggregation/ I.M. James // J. Hum. Hypertens.-1988.-Vol.2.-P. 21−25.
- Jones C.J. Abnormal arterial flow pattern in untreated essential hypertension: possible link with the development of atherosclerosis/ C.J. Jones, D.R. Singer, N.V. Watkins et al. // Clin. Sei. Colch.-1990.-Vol.78.-P.43 1−435.
- Joint Recomendations of the British Cardiac Society, British Hyperlipidemia Association, British Diabetic Association on Prevention of Coronary Heart Disease in Clinical Practice // Heart.-1998.-Vol.80.-Suppl.2.-P. 1−28.
- Johnstone M.T. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus /M.T. Johnstone, S.J. Creager, K.M.Scales // Circulation.-1993.-Vol.88.-P. 2510−2516.
- Julius S. The hemodynamic link between insulin resistance and hypertension / S. Julius, T. Gudbrandsson, K. Jamerson// J. Hypertens.-1991.-Vol. 9.-P. 983−986.
- Kalinowski L. Third-generation ?-blockers stimulate nitric oxide release from endothelial cells through ATP efflux/ L. Kalinowski, L.W. Dobrucki, M. Szczepanska-Konkel et al. // Circulation. -2003.-Vol. 107.-P.2747−275 2.
- Kannel W.B. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile / W.B. Kannel // Am. Heart J.-1999.-Vol. 138.-P. 205−210.
- Kaplan K.L. Plasma levels of beta-thromboglobulin of Captopril on platelet aggregation in vivo/ K.L. Kaplan., L. Owen // Blood.-1981.-Vol.57.-P. 199−202.
- Kasiske B.L., Ma J.Z., Roberto S.N. et al. Effects of antihypertensive therapy on serum lipids / B.L.Kasiske., J.Z. Ma, S.N. Roberto et al. //Ann. Intern. Med.-1995.-Vol. 122.-P. 133−141.
- Kendall M.J. Conventional versus newer antihypertensive therapies a draw / M.J. Kendall // Lancet.-1999.-Vol.354.-P. 1744−1745.
- Kugiyama K. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries / K. Kugiyama, H. Doi, T. Motoyama et al. // Circulation.-1998.-Vol. 97.-P.2519−2526.
- Kosegawa I. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivityin patients with essential hypertension / I. Kosegawa, M. Inaba, T. Morita et al. // Clin. Exp. Hypertens.-1998.-Vol.20.-P.75 1−761.
- Kung S.F. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta / S.F. Kung// Hypertension.-1995.-Vol.25.-P. 194−200.
- Kuperstein R. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass / R. Kuperstein, Z. Sasson // Circulation.-2000.-Vol.102.-P.1802−1805.
- Lakshman M.R. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension / M.R. Lakshman, D.J. Reda, B.J. Matersib et al. // Arch. Intern. Med.-1999.-Vol. 1 59.-P.55 1−558.
- Landin K. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease / K. Landin, L. Tengborn, U. Smith // J. Intern. Med.-1990.-Vol. 227.-P.273−278.
- Lee C.R. Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension / C.R. Lee, H.M. Bryson.// Drugs.-1994.-Vol. 48.-P.274−296.
- Li J. Noninvasive detection of endothelial dysfunction in patients with essential hypertension / J. Li, S.P. Zhao, X.P. Li // Int. J. Cardiol.-1997.-Vol.61.-P. 165−169.
- Lind L. ndothelium-dependent vasodilatation in hypertension: a review / L. Lind, S.-O.Granstam, J. Millgard / Blood Pres.-2000.-Vol. 9.-P.4−15
- Linder L. Indirect evidence for the release of the endothe-lium-derived relaxing in the human forearm circulation in vivo /L. Linder, W. Kiowski, F.R. Buhler// Circulation.-1990.-Vol.81 .-P. 1762−1767.
- Lithell H. Hypertension and hyperlipidemia // Am. J. Hyper-tens.- 1993.-Vol.6.-P.303−308.
- Lip G.Y.H. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?/ G.Y.H. Lip, A.D. Blann // Cardiovasc. Res.-1997.-Vol.34.-P.255−265.
- Lip G.Y.H. Relationship of endothelium, thrombogenesis, and haemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy / G.Y.H. Lip, A.D. Blann // Am. J. Cardiol.-1997.-Vol.80.-P.1566−1571.
- Lip G.Y.H. Hypertension and the prothrombotic state / G.Y.H. Lip // Journal of Human Hypertension.-2000.-Vol. 14.-P.687−690.
- Lip G.Y.H. Does hypertension confer a prothrombotic state? Virchow’s triad revisited/ G.Y.H. Lip, A.D. Blann // Circulation.-2000.-Vol.101.-P.218−220.
- Luscher T.F. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat / T.F. Luscher, P.M.Vanhoutte // Hypertension.-1986.-Vol.8.-P.344−348.
- Luscher T.F. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats / T.F. Luscher, L. Raji, P.M. Vanhoutte // Hypertension.-1987.-Vol.9.-P. 157−163.
- Luscher T.F. Endothelium-derived contracting factors / T.F. Luscher, Ch. Boulanger, Y. Dohi // Hypertension.-1992.-Vol. 19.-P.117−130.
- Luscher T.F. Receptor-mediated endothelial vascular regulation/ T.F. Luscher // Arzneimittelforschung.-1994.-Vol. 44.-P.418−419.
- Luscher T.F. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator/ T.F. Luscher, G. Noll// Atherosclerosis.-1995.-Vol. 118.-P.81−90.
- Luscher T.F. Endothelial function as an end-point in interventional trials: concepts, methods and current data / T.F. Luscher, G. Noll// Hypertens.-1996.Vol. 14.-Suppl.2.-P. 111−119.
- Luscher T.F. Endothelial dysfunction as a therapeutic target. The ENCORE trials // Eur. Heart J.-2000.-Vol. 2.-Suppl.D.-D20-D25.
- Mayhan W.G. Impairment of endothelium-dependent responses of cerebral arterioles in chronic hypertension / W.G. Mayhan, F.M. Faraci, D.D. Heistad // Am. J. Physiol.-1987,-Vol.253.-P.1435−1440.
- Mayhan W.G. Impairment of endothelium-dependent dilation of basilar artery during chronic hypertension / W.G. Mayhan // -Am. J. Physiol.-1990.-Vol.259.-P.1455−1462.
- Malek A.M. Hemodynamic shear stress and its role in atherosclerosis / A.M. Malek, S. L. Alper., S. Izumo // J.A.M.A.-1999.-Vol.282.-P.2035−2042.
- MacMahon S. Blood pressure, stroke and coronary heart disease / S. MacMahon // Lancet.-1990-Vol.335.-P.765−774.
- Majumdar S. Beta-blockers for the treatment of hypertension in patients with diabetes: exploring the contraindication myth/S. Majumdar // Cardiovasc. Drugs Ther.-1999.-Vol.13.-P. 435−439.
- Mannucci P.M. Von Willebrand factor a marker endothelial damage? / P.M. Mannucci // Arterioscler Thromb Vask Biol.-1998.-Vol.18.-P. 1359−1362.
- Mattei P. Endothelial function in hypertension / P. Mattei, A. Virdis, L. Ghiadoni // J. Nephrol.-1997.-Vol. 10.-N.4.-P. 192−197.
- Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results // Br. Med. J.-1985 .-Vol.291.-P.97−104.
- Meyer G.R. Vascular endothelial dysfunction / G.R. Meyer, A.G. Herman // Prog. Cardiovasc. Dis.-1997.-Vol. 39.-№.4.-P.325−342.
- Millgard J. Divergen effects of different antihypertensive drugs on on endothelium-dependent vascular relaxation in the human forearm / J. Millgard, L. Lind // J. Cardiovasc. Pharmacol.-1998.-Vol. 32.-P. 406−412.
- Muiesan M. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension / M. Muiesan, M. Salvetti, C. Monteduro // Hypertension.-1999.-Vol. 33.-P.575−580.
- Muraki K. Nifedipine and nisoldipine modulate membrane potential of vascular endothelium via a myoendothelial pathway / K. Muraki, M. Watanabe, Y. Imaizumi // Life Sci.- 2000.-Vol. 67.-P.3 163−3170.
- Niklason A. Development of diabetes is retarded by ACE inhibition in hypertensive patients—a subanalysis of the Captopril Prevention Project (CAPPP)/ A. Niklason, T. Hedner, L. Niskanen // J. Hypertens.-2004.-Vol.22.-P.463−465.
- Noll G. Endothelium and high blood pressure / G. Noll, M. Tschudi, E. Nava // Int. J. Microcirc. Clin. Exp.-1997.-Vol. 17.-P.273−279.
- O’Malley T. Platelet platelet activation in patients with hypertension, volume in stroke patients / T. O’Malley, P. Lang-horne, R.A. Elton // Stroke.-1995.-Vol.26.-P.995−999.
- Oparil S. Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)/ S. Oparil// Hypertension.2003.-Vol.41.-P.1006−101 1.
- Opie L.H. Mechanisms where by calcium channel antagonists may protect patients with coronary artery disease / L.H.Opie// Eur. Heart. J.-1997.-Vol. 18.-Suppl. A.-A9-A12.
- Padwal R. Evidence based management of hypertension Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review / R. Padwal, Sh. E. Straus, F. A. McAlister // B.M.J.- 2001 .-Vol.322-P.977−980.
- Pahor M. Health outcomes associated with calcium antagonists compared with other first-line anti-hypertensive therapies: a meta-analysis of randomised controlled trials / M. Pahor // Lancet.-2000.-Vol. 35 6.-P. 1949−1954.
- Palmer R.M.J. Vascular endothelial cells synthesize nitric oxide from L-arginine / R.M.J. Palmer, D.S. Ashton, S. Moncada // Nature.-1988.-Vol.333.-P.524−526.
- Patel S.T. Risk factors and their role in the disease of the arterial wall / S.T. Patel, K.C. Kent // Semin. Vase. Surg.-1998.-Vol.l 1.-P. 156−168.
- Panza J.A. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension / J.A. Panza, A.A. Quyyumi, Jr.J.E. Brush et al. // N.Engl.J.Med.-1990.-Vol. 323.-P.22−27.
- Panza J.A. Endothelial dysfunction in essential hypertension / J.A. Panza // Clin. Cardiol.-1997.-Vol.1 l.-Suppl.II.-P.26−33.
- Pepine C.J. Clinical implications of endothelial dysfunction/ C.J. Pepine // Clin. Cardiol.-1998.-Vol.21 .-P.795−799.
- Perticone F. Prognostic significance of endothelial dysfunction in hypertensive patients. / F. Perticone, R. Ceravolo, A. Pujia et al. // Circulation.- 2001.-Vol.104.-P.191−196.
- Perez S. Calcium channel blockers: do they have pleiotropic effects on atherosclerosis? / S. Perez // J.Hum. Hypertens.-2000.~ Vol. 14.- Suppl 1.- P.96−99.
- Perticone F. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients / F. Perticone, R. Ceravolo, R. Maio et al. // Cardiovasc. Res.-1999.-Vol.41.-P.299 -306.
- Poli K.A. Association between blood pressure and fibrinolytic potential in the Framingham Offspring population / K.A. Poli, G.H. Tofler, M.G. Larson // Circulation.-2000.-Vol.101 .-P.264−269.
- Phillips G.B. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension / G.B. Phillips, T.Y. Jing, L.M. Resnick // J.Hypertens.-1993.-Vol. 11.-P.699−702.
- PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108individuals with previous stroke or transient ischaemic attack // Lancet.-2001.-Vol. 358.-P. 1033−1041.
- Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other Societies of coronary prevention // Eur. Heart. J.-1998.-Vol. 19.-P. 1434−1503.
- Pober J.S. Cytokine mediated activation of vascular endothelium / J.S. Pober // Am. J. Pathol.- 1988.-Vol.133.-P.426−433.
- Quyyumi A.A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease / A.A. Quyyumi // Am. J. Med.-1998.-Vol. 6.-№ 105.-P.32−39.
- Rafflenbeul R. Prognostic benefits of antihypertensive therapy: concern about another «solid» meta-analysis / R. Rafflenbeul // Br. J. Cardiol.-2000.-Vol.7.-P.703−708.
- Raitakari O.T. Testing of endothelial dysfunction / O.T. Rai-takari, D.S. Celermajer // Ann. Med.- 2000.-Vol.32.-P.293−304.
- Ram C.V. Antiatherosclerotic effects of calcium channel blockers: therapeutic implications / C.V.Ram // Cardiology.-1993.-Vol.10.-P.77−83.
- Ramsay L.E. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society 1999/ L.E. Ramsay // J. Hum. Hypertens.-1999.-Vol. 13.-P.569−592.
- Reavan G. Banting Lecture 1988. Role of insulin resistance in human disease/ G. Reavan // Diabetes.-1988.-Vol.37.-P.1595−1607.
- Ribben A. Effect of nitrendipine and tiapamil on Ca2+ influx and on platelet aggregation / A. Ribben // J. Cardiovasc. Pharmacol.-1987.-Vol. 10.-Suppl 10.-P.68−69.
- Rigaud A.S. Cerebral complications of hypertension / A.S. Rigaud, M.L. Seux, J.A. Staessen // J. Hum. Hypertens.-2000.-Vol. 14.-P.605−616.
- Rossner S. Long term propranolol treatment and changes in body weight after myocardial infarction / S. Rossner, C.L. Taylor, R.P. Byington et al. // B.M.J.-1990.-Vol.300.-P.902−903.
- Ruggeri R.Z. Role of von Willebrand factor in platelet thrombus formation / R.Z. Ruggeri //Ann. Med.-2000.-Vol.32.-P. 2−9.
- Ruschitzka F.T. Combination of ACE inhibitors and calcium antagonists: a logical approach / F.T. Ruschitzka, G. Noll, T.F. Luscher // J. Cardiovasc. Pharmacol.-1998.-Vol. 31.- Suppl. 2.-S5-S16.
- Schachinger V. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease / V. Schachinger, M.B. Britten, A. M. Zeiher // Circulation.-2000.-Vol.101.-P.1899−1906.
- Schiffrin L.E., Deng L.Y. Structure and function of resistance arteries of hypertensive patients treated with a B-blocker or a calcium channel antagonist / L.E. Schiffrin, L.Y. Deng // J. Hyper-tens.-1996.-Vol. 14.-P. 1247−125 5.
- Schneider W. Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonist?
- W. Schneider // Euro. J. Clin. Pharmacol. -1990.-Vol. 30.-Suppl 1.-S17-S23.
- Schrier R.W. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke / R.W. Schrier, R.O. Estacio, A. Esler et al. // Kidney Int.-2002.-Vol.61.-P. 1086−1097.
- Schroeder J.S. Calcium blockers and atherosclerosis: lessons from the Stanford transplant coronary artery disease/Diltiazem Trial / J.S. Schroeder, S. Gao // Can. J. Cardiol. 1995.-Vol. 11 .-P.710−715.
- Schweizer J. Effect of high dose verapamil on restenosis after peripheral angioplasty / J. Schweizer // J.A.C.C.-1998.-Vol.31.-P.1299−1305.
- Selwyn A.P. Cell dysfunction in atherosclerosis and ischemic manifestations of coronary artery disease / A.P. Selwyn, S. Kinlay, M. Creager et al. // Am.J.Cardiol.-1997.-Vol. 79.-P.17−23.
- Sica D. A. Old Antihypertensive agents-diuretics and b-blockers: do we know how and in whom they lower blood pressure? / D. A. Sica // Cur. Hypertens. Rep.-1999.-№ 1 .-P.296−304.
- Shimokawa H. Endothelial dysfunction in hypertension / H. Shimokawa // J. Atheroscler. Thromb.-1998.-Vol.4.-P.l 18−127.
- Shepherd J.T. Endothelium-derived vasoactive factors: I. En-dothelium-dependent relaxation / J.T. Shepherd, Z.S. Katusic // Hypertension.-1991- Vol. 18.-P.76−85.
- Sechi L. A. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension / L. A. Sechi, L. Zingaro, C. Catena et al. // Hypertension.-2000.-Vol.36.-P.978−981.
- Spencer C.G.C. Haemorheological factors in hypertension / C.G.C. Spencer, G.Y.H. Lip // J. Hum. Hypertens.-2000.-Vol. 14.-P.291−293.
- Simpson F.O. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk // J. Hypertens.-1996.-Vol. 14.-P.683−689.
- Stadler R.W. Mesurment of the time course of periferal vasoactivity: results of cigurette smokers / R.W. Stadler, S.F. Ibrahim, R.S. Lees // Atherisclerosis.-l998.-Vol. 138.-№ 1.-P.197−206.
- Staessen J.A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (Isolated Systolic Hypertension) / J.A. Staessen // Lancet.-l 997.-Vol.350.-P.757−764.
- Staessen J.A. Cardiovascular prevention and blood pressure reduction / J.A. Staessen, J. Wang, L. Thijs // J. Hypertens.-2003.-Vol.21.-P.1055−1076.
- Suwaidi J.A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction / J.A. Suwaidi, S. Hamasaki, S.T. Higano et al. // Circulation.-2000.-Vol.101.-P.948 -954.
- Suzuki M. Improvement of insulin resistance in essential hypertension by long-acting Ca antagonist benidipine / M. Suzuki, A. Kanazawa, M. Hasegawa et al. // Clin. Exp. Hypertens.-1999.-Vol.21.-P.1327−1344.
- Taddei S. Vasodilation to acetylcholine in primary and secondary forms of hypertension / S. Taddei, A. Virdis, P. Mattei et al. // Hypertension.-1993.-Vol.21.-P.929−933.
- Taddei S. Pathogenetic factors in hypertension. Endothelial factors / S. Taddei, A. Salvetti // Clin. Exp. Hypertens.-1996.-Vol. 18.-P. 323−335.
- Taddei S. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients / S. Taddei, A. Virdis, L. Ghiadoni et al. // Hypertension.-1997.-Vol.30.-P. 1606 -1612.
- Taddei S. Endothelial dysfunction in hypertension: fact or fancy? / S. Taddei, A. Virdis, L. Ghiadoni et al. // J. Cardiovasc. Pharmacol.-1998.-Vol. 32.-№ 3.-P.41−47.
- Taddei S. The role of endothelium in human hypertension / S. Taddei, A. Virdis, L. Ghiadoni et al. // Curr. Opin. Nephrol. Hy-pertens.-1998.-Vol.7.-P.203−209.
- Taddei S. Different effect of a calcium-antagonist and a beta-blocker on nitric oxide availability in essential hypertensive patients / S. Taddei, A. Virdis, L. Ghiadoni et al. // J. Hypertens.-1999.-Vol. 17.-P.129−132.
- Takahara K. Effect of nifedipine on platelet function // Am. Heart. J.-1985.-Vol.109.-P.4−8.
- Tikkanen H.O. Skeletal muscle fiber distribution influences serum high-density lipoprotein cholesterol level / H.O. Tikkanen, H. Naveri, M. Harkonen // Atherosclerosis.-1996.-Vol.120.-P.1−5.
- Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics / N. Toda // Pharmacology and Therapeutics.-2003.-Vol. 100.-№ 3.-P.215−234.
- Tominaga M. Hypertension and ageing impair acetylcholine-induced vasodilation in rats / M. Tominaga, K. Fujii, I. Abe // J. Hypertens.-1994.-Vol. 12.-P.259−268.
- The MRIFT Research Group. Multiple Risk Factor Intervention Trial. Risk Factor changes and mirtality results // J. Am. Med. Assoc.-1982.-Vol.248.-P. 1465−1477.
- The effect of treatment on mortality in 'mild' hypertension: results of the Hypertension Detection and Follow-up Program. // N. Engl. J. Med.-1982.-Vol.307.-P.976−980.
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, rami-pril, on cardiovascular events in high-risk patients // N. Engl. J. Med.-2000.-Vol. 342.-P. 145−153.
- Treasure C.B. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients / C.B. Treasure, S.V. Manoukian, J.L. Klein et al. // Circ. Res.-1992.-Vol.71.-P.776−781.
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type II diabetes: UKPDS // B.M.J.-1998.-Vol.317.-P.713−720.
- Van Zwieten P.A. Endothelial dysfunction in hypertension. A critical evaluation / P.A. Van Zwieten // Blood Press.-1997.-Vol.2.-P.67−70.
- Vanhoutte P.M. Endothelium-dependent responses in hypertension / P.M. Vanhoutte, C.M. Boulanger // Hypertens. Res.-1995.-Vol.18.-P.87−98.
- Vanhoutte P.M. Endothelial dysfunction in hypertension / P.M. Vanhoutte // J. Hypertens.-1996.-Vol. 14.-P.83−93.
- Vazquez J. Actualizacio’n en terapia tromboli’tica / J. Vazquez, F. Contreras, M. Velasco // Archivos Venezolanos de Farmacologi’a y Terape’utica.-1999.-Vol.l8.-P.59−70.
- Verma S. Fundamentals of endothelial function for the clinical cardiologist / S. Verma, T.J. Anderson // Circulation.- 2002.-Vol. 105.-P.546−551.
- Vilen L. The peripheral platelet count and ADP-induced platelet aggregation in response to metoprolol and propranolol as studied in young healthy male volunteers / L. Vilen, J. Kutti, K. Freden et al. // Scand.J.Haematol.-1983.-Vol.31.-P.440−446.
- Vita J.A. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease / J.A. Vita, C.B. Treasure, E.G. Nabel et al. // Circulation.-1990.-Vol.81 .-P.491−497.
- Vita J.A., Keaney J.F.Jr. Endothelial function a barometer for cardiovascular risk? // Circulation.-2002.-Vol. 106.-P.640−642.
- Vischer U.M. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide levels / U.M. Vischer, J. Ingerslev, C.B. Wollhrim et al. // Thromb. Haemost.-1997.-Vol.77.-P.387−393.
- Vogel R.A. Coronary risk factors, endothelial function, and atherosclerosis: a review / R.A. Vogel // Clin. Cardiol.-1997,-Vol.20.-№ 5.-P.426−432.
- Voorde J. Endothelium-dependent and independent relaxation of aortic rings from hypertensive rats / J. Voorde, I. Leusen // Am. J. Physiol.-1986.-Vol.251.-P.711−717.
- Walker L.N. Morphology and cell kinetis of fatty streak lesion lormation in the hypercholesterolemic rabbit / L.N. Walker, M.A. Reidy, D.E. Bowyer // Am. J. Pathol.-Vol.125.-P.450−459.
- Watanabe H. Carvedilol improves endothelial dysfunction in patients with essential hypertension / H. Watanabe, K. Nakagawa // Circulation.-1999.-Vol.100.-S.I-P.S 104-S107.
- Weistein D.B. Protective actions of calcium channel antagonist in atherogenesis and experimental vascular injury / D.B. Weistein, J.G. Heider // Am. J. Hypertens.-1989.-Vol.2.-P. 205 212.
- Williams S.B. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus / S.B. Williams, J.A. Cusco, M.A. Roddy // J.Am. Coll. Cardiol.-1996.-Vol. 27.-P.567−574.
- Wing L.M.H. A comparision of outcomes with angiotensin-converting enzime ingibitors and diuretics for hypertension on elderly / L.M.H. Wing, P. Reid, P. Ryan et al. // N.Engl.J.Med.-2003.-Vol.348.-P.583−592.
- Wiklund O. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia. A 3-Year randomized study / O. Wiklund, J. Hulthe, J. Wikstrand et al. // Stroke.-2002.-Vol.33.-P.572−576.
- Wikstrand J. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study / J. Wikstrand, I. Warnold, J. Tuomilehto et al. // Hypertension.-1991.-Vol.17.-P.570−588.
- Wilhelmsen L. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial / L. Wilhelmsen, G. Berglund, D. Elmfeldt et al. // J. Hypertens.-1987.-Vol.5.-P.561−572.
- Wever R.M.F. Atherosclerosis and the two faces of endothelial nitric oxide synthase / R.M.F. Wever, T.F. Luscher // Circulation.-1998.-Vol.97.-P. 108−112.
- World Health Organization. Obesity: preventing and managing the global epidemic of obesity. Report of the WHO Consultation of Obesity. Geneva, 3−5 June 1997.
- Yang J. Pranidipine enhances the action of nitric oxide released from endothelial cells / J. Yang, K. Fukuo, S. Morimoto et al. // Hypertension.- 2000.-Vol.35.-P.82−90.
- Yusuf S. Beta-blockade during and after myocardial infarction: an overview of the randomized trials / S. Yusuf, R. Peto, J. Lewis et al. // Progr. Cardiov. Dis.-1985.-Vol. 27-P. 335 371.
- Zanchetti A. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group / A. Zanchetti,
- Hansson, J. Me’nard // J. Hypertens.-2001.-Vol. 19.-P.819−825.
- Zanchetti A. Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach / A. Zanchetti, G. Mancia // J. Hypertens.-1996.-Vol. 14.-P.809−811.